Share |
News

T-Ray Science Completes Private Placement


November 29, 2010 at 8:45 pm

Vancouver, Canada: T-Ray Science, Inc. (TSX-V: THZ) announces that it has completed a private placement of 1,250,000 units (“Units”) at a price of $0.20 per Unit for gross proceeds of $250,000.  Each Unit consists of one common share of the Company and one half common share purchase warrant, each full warrant entitling the holder thereto to acquire a common share at a price of $0.30 for a period of 12 months from the date of issuance.

In addition, the Company will pay an 8% cash finder’s fee to a party that referred the subscriber to the Company.

The securities issued are subject to a hold period based on applicable securities laws from the date of issuance.  Completion of the private placement is subject to final acceptance of the TSX Venture Exchange.

About T-Ray Science, Inc.

T-Ray Science, Inc. is a medical device company committed to developing innovative systems for the early detection of cancer.     

The Company’s initial focus is skin cancer, including basal cell carcinoma, squamous cell carcinoma, and melanoma. The Company has exclusive world-wide rights to a technology developed by the BC Cancer Agency for in vivo, real-time, non-invasive skin measurements.

Our platform technology is also fully extensible to early detection systems for other types of cancer, including lung, gastro-intestinal, colorectal and cervical cancers.

The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 
For further information contact:

T-Ray Science, Inc.
Thomas Braun, President & CEO              
Telephone: 1-877-605-0507

Email: info@t-rayscience.com
Website:  www.t-rayscience.com


Forward Looking Statements

This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of THz based products, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand.  These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.

  Back to top